Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled study

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 9, 1998, Pages 3169-3176

  Fonseca, Vivian A ^a   Valiquett, Thomas R ^b   Huang, Saling M ^b   Ghazzi, Mahmoud N ^b   Whitcomb, Randall W ^b   Blevins, Thomas ^c   Cohen, Joshua ^c   Dawson, Keith ^c   Friedman, Neal ^c   Gerstein, Hertzel ^c   Goldstein, Barry ^c   Gumbiner, Barry ^c   Hone, Jennifer ^c   Hsueh, Willa ^c   Kelly, David ^c   Lucas, K Jean ^c   Maggiacomo, Frank ^c   Mitchell, William ^c   Olefsky, Jerrold ^c   Peters, Ann ^c   Plevin, Sanford ^c   Polonsky, Kenneth ^c   Ross, Stuart ^c   Schwartz, Sherwyn ^c   Schulman, Gerald ^c   Sims, Richard ^c   Synder, James ^c   Suwannasri, Ruenrudee ^c   more..

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b PFIZER INC   (United States)

^c Parke Davis/Warner Lambert Res Div ^*

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SCREENING; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; C-PEPTIDE; CHROMANS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PLACEBOS; SULFONYLUREA COMPOUNDS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 7844236780     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.9.3169     Document Type: Article

References (22)

1. Kruszynska YT, Olefsky JM. 1995 Cellular and molecular mechanisms of non-insulin dependent diabetes mellitus. J Invest Med. 44:413-428.
2. Kuehnle HF. 1996 New therapeutic agents for the treatment of NIDDM. Exp Clin Endocrinol Diabetes. 104:93-101.
3. Pimenta W, Korytkowski M, Mitrakou A, et al. 1995 Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA. 273:1855-1861.
4. Berson SA, Yalow RS. 1970 Insulin "antagonist" and insulin resistance. In: Ellenberg M, Rifkin H eds. Diabetes mellitus: theory and practice. New York: McGraw-Hill; 388-423.
5. Saltiel AR, Olefsky JM. 1996 Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1661-1669.
6. Whitcomb RW, Saltiel AR, Lockwood DH. 1996 New therapies for non-insulin-dependent diabetes mellitus: thiazolidinediones. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes mellitus. Philadelpbia: Lippincott-Raven; 661-668.
7. Kuzuya T, Iwamoto Y, Kosaka K, et al. 1991 A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus. Diab Res Clin Pract. 11:147-154.
8. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. 1996 Effect of combination therapy of troglitazone and sulphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabetic Med. 13:365-370.
9. Tukey JW, Ciminera JL, Heyse JF. 1985 Testing the statistical certainty of a response to increasing doses of a drug. Biometrics. 41:295-301.
10. Dunett CW. 1955 A multiple comparison procedure for comparing several treatments with a control. J Am Statist Assoc. 50:1096-1121.
11. Dunett CW. 1964 New tables for multiple comparisons with a control. Biometrics. 20:482-91.8.
12. American Diabetes Association. 1998 Consensus development conference on insulin resistance. Diabetes Care. 21:1-5.
13. American Diabetes Association. 1997 Standards of medical care for patients with diabetes mellitus. Diabetes Care 20[Suppl 1]:S5-S13.
14. 2+ channel activity. Am J Physiol. 270:E133-E140.
15. Byrne M, Sturis J, Polonsky K. 1995 Insulin secretion and clearance during low-dose graded glucose infusion. Am J Physiol. 28:E21-7.13.
16. Valiquett TR, Balagtas CC, Whitcomb RW, Lockwood DH. 1994 Troglitazone dose response study in patients with noninsulin dependent diabetes. Clin Res. 42:400.
17. Ghazzi M, Radke-Mitchell L, Venable T, Troglitazone Study Group, Whitcomb R. 1997 Troglitazone improves glycemic control in patients with type II diabetes who are not optimally controlled on sulfonylurea. Diabetes. 46[Suppl 1]:44A (Abstract).
18. Oakes N, Kennedy C, Jenkins A, Faybutt D, Chisholm D, Kraeger E. 1994 A new antidiabetic agent, BRL 49653 reduces lipid availability and improves insulin action and glucoregulation. Diabetes. 43:1203-1210.
19. Rebrin K, Steil G, Getty L, Bergman R. 1995 Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes. 44:1038-1045.
20. Ferrannini E, Barret E, Bevilacqua S, DeFronzo R. 1983 Effect of fatty acids on glucose production and uptake in man. J Clin Invest. 72:1737-1747.
21. Krauss RM. 1995 Dense low density lipoproteins and coronary artery disease. Am J Cardiol. 75:53B-57B.
22. Tack CJJ, Smits P, Demacker PNM, Stalenhoef AFH. 1998 Troglitazone decrease the proportion of small, dense LDL and increases the resistance of ldl to oxidation in obese subjects. Diabetes Care. 21:796-799.